A.HogeneschJ
Designed solely for parenteral use (drug administration by intravenous, intramuscular, or subcutaneous injection) following the addition of drugs that require dilution or must be dissolved in an aqueous vehicle prior to injecting
In addition to its use in ulcerative colitis clinical trials[2-7] and its effectiveness in various models of colitis[30-35], BPC 157 reduces high myeloperoxidase (MPO) activity in colonic tissue[33], heals fistulas[36-38], rescues failed anastomosis healing[30,34,39,40] and markedly improves intestinal adaptation following massive bowel resection[40]
Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation
Molecular targeted study in tumors: From western medicine to active ingredients of traditional Chinese medicine